- Home
- NUAI vs PHGE Comparison
NUAI vs PHGE Comparison
Compare NUAI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUAI
- PHGE
- Stock Information
- Founded
- NUAI N/A
- PHGE 2015
- Country
- NUAI United States
- PHGE Israel
- Employees
- NUAI N/A
- PHGE N/A
- Industry
- NUAI Oil & Gas Production
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- NUAI Energy
- PHGE Health Care
- Exchange
- NUAI Nasdaq
- PHGE Nasdaq
- Market Cap
- NUAI 11.3M
- PHGE 10.4M
- IPO Year
- NUAI N/A
- PHGE N/A
- Fundamental
- Price
- NUAI $0.40
- PHGE $0.47
- Analyst Decision
- NUAI
- PHGE Strong Buy
- Analyst Count
- NUAI 0
- PHGE 1
- Target Price
- NUAI N/A
- PHGE $15.00
- AVG Volume (30 Days)
- NUAI 7.1M
- PHGE 441.1K
- Earning Date
- NUAI 08-14-2025
- PHGE 08-13-2025
- Dividend Yield
- NUAI N/A
- PHGE N/A
- EPS Growth
- NUAI N/A
- PHGE N/A
- EPS
- NUAI N/A
- PHGE N/A
- Revenue
- NUAI $718,761.00
- PHGE N/A
- Revenue This Year
- NUAI N/A
- PHGE N/A
- Revenue Next Year
- NUAI N/A
- PHGE N/A
- P/E Ratio
- NUAI N/A
- PHGE N/A
- Revenue Growth
- NUAI 14.80
- PHGE N/A
- 52 Week Low
- NUAI $0.32
- PHGE $0.34
- 52 Week High
- NUAI $12.29
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- NUAI N/A
- PHGE 44.76
- Support Level
- NUAI N/A
- PHGE $0.45
- Resistance Level
- NUAI N/A
- PHGE $0.51
- Average True Range (ATR)
- NUAI 0.00
- PHGE 0.03
- MACD
- NUAI 0.00
- PHGE -0.01
- Stochastic Oscillator
- NUAI 0.00
- PHGE 19.83
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).